Ekta Bagri on Muck Rack

Ekta Bagri

Kolkata
As seen in: Zacks Investment Research, Yahoo Singapore, Yahoo Finance, Yahoo Finance Australia, Yahoo Finance Singapore, Yahoo Finance UK, Nasdaq, Yahoo Finanzas, Barchart, The Eastern Progress
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ekta

Contact Ekta, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?

|
By Ekta Bagri
| Yahoo Finance Verified
Harmony Biosciences Holdings, Inc. HRMY sits at an interesting point for investors. The stock looks inexpensive by several valuation measures, but the company depends heavily on Wakix for revenues. That creates a balanced buy debate. HRMY has a profitable commercial franchise and a funded pipeline, yet recent misses keep the setup from looking one-sided. HRMY's valuation profile is the clearest part of the bull case.
Open in Who Shared View Duplicates (3) Issue with article?

HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase

|
By Ekta Bagri
| Yahoo Finance Verified
Harmony Biosciences Holdings, Inc. HRMY is no longer only a Wakix revenue story. The company is using its sleep-wake franchise to fund a broader neuroscience strategy. The central question is whether those emerging growth trends can turn pipeline investment into a more diversified business before competition and exclusivity risks pressure the core product. Harmony is working to extend pitolisant beyond its established narcolepsy base.
Open in Who Shared View Duplicates (3) Issue with article?

Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline

|
By Ekta Bagri
| Yahoo Finance Verified
Harmony Biosciences Holdings, Inc. HRMY is trying to turn a successful narcolepsy franchise into a broader neuroscience platform. The transition is funded by Wakix, which still does most of the commercial work. The question for investors is whether that cash-generating base can keep expanding while newer pitolisant products and non-pitolisant assets move closer to commercial relevance. Wakix remains Harmony's core commercial engine.
Open in Who Shared View Duplicates (4) Issue with article?
See all 307 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified